Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219251 | 0.77 | CYP11B1 (0.42) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL13515213 | 0.75 | CYP11B2 (0.43) | CYP1A2CYP3A4FYN | |
| SCHEMBL11916056 | 0.73 | PPARA (0.33) | PPARAPIM1PIM3PIM2FYN | |
| SCHEMBL206865 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL3650459 | 0.69 | PPARA (0.42) | CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL830961 | 0.69 | NOS3 (0.36) | — | |
| SCHEMBL23586794 | 0.66 | NPC1 (0.44) | — | |
| SCHEMBL22869121 | 0.66 | CYP11B2 (0.45) | PIM1PIM3 | |
| SCHEMBL23502438 | 0.66 | CTSS (0.52) | PIM1PIM3PIM2 | |
| SCHEMBL10687683 | 0.65 | CYP2D6 (0.40) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | CYP1A2 673/4885CYP3A4 848/4885CYP2D6 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.